Monday, June 30, 2025 6/30/2025

Targeting medium chain fatty acid metabolism for the treatment of chronic Graft-versus-Host Disease

Award Number: R01HL166820
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2023
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

Targeting medium chain fatty acid metabolism for the treatment of chronic Graft-versus-Host Disease - Abstract Chronic graft versus host disease (cGVHD) has emerged as one of the major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). However, there is limited therapeutic option for cGVHD prevention and therapy. Steroid, the standard initial therapy of cGVHD, often is unsuccessful in preventing permanent organs damage and has been associated with significant toxicities. Fatty acid (FA) metabolism decides T cell (Tc) fate and function in cGVHD development. However, how medium chain fatty acid (MCFA) participates in cGVHD pathobiology has not been studied. GPR84 has been well known as the MCFA sensing receptor. Using peripheral blood nonnuclear cells (PBMCs) and fecals from cGVHD patients along with murine models of cGVHD, we elucidate the implication of GPR84 signaling in cGVHD pathobiology. The scientific premise of current research proposal is to understand how GPR84- mediated MCFA signaling regulates T cell metabolism in cGVHD and therefore validate GPR84 targeting as an effective approach to control cGVHD. In Aim 1, we will elucidate the biological function of GPR84-mediated MCFA metabolism in cGVHD. We will use GPR84 genetically knockout mice and MCFA- enriched diet to understand the role of MCFA signaling in bronchiolitis obliterans (BO)-, and thymus-damaged cGVHD. In Aim 2, we will elucidate mechanisms responsible for the impact of GPR84- mediated MCFA signaling in cGVHD pathobiology. Utilizing stable isotope-resolved metabolomics, high dimensional flow cytometry, and single cell ATAC-seq, we will validate how GPR84 signaling by regulating cellular metabolism would influence Tc and follicular helper Tc (TFH) survival, migration, differentiation, and function. We will elucidate the function CD8+T follicular cells (TFC), which is found enriched in cGVHD patient’s PBMCs and elucidate how GPR84 signaling regulates this novel cell subset post- transplant. In Aim 3, we investigate whether GPR84 targeting would be a therapeutic option for cGVHD while preserving the GVL effect. We will use a combination of pharmacological antagonist; CRISPR-cas9 induced gene silencing, and diet programming approaches with human-to-mouse cGVHD model to test our hypothesis. We will also examine if GPR84 targeting would be effective in the prevention steroid refractory cGVHD. Because GPR84 inhibitor GLPG1205 has been found safe and effective in phase 2 clinical; precise dietaries and microbiome- modulating therapies are important in the treatment of cGVHD, current research proposal is highly translational and critically important.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $544,260 )
2025	2025	THE UNIVERSITY OF CENTRAL FLORIDA BOARD OF TRUSTEES	4000 CENTRAL FLORIDA BLVD	ORLANDO	FL	32816	ORANGE	USA	Blood Diseases and Resources Research	001	3	5/28/2025	NON-COMPETING CONTINUATION	$54,426
2025	2025	THE UNIVERSITY OF CENTRAL FLORIDA BOARD OF TRUSTEES	4000 CENTRAL FLORIDA BLVD	ORLANDO	FL	32816	ORANGE	USA	Blood Diseases and Resources Research	000	3	4/29/2025	NON-COMPETING CONTINUATION	$489,834
														Subtotal = $544,260

Issue Date FY: 2024 ( Subtotal = $542,119 )
2024	2024	THE UNIVERSITY OF CENTRAL FLORIDA BOARD OF TRUSTEES	4000 CENTRAL FLORIDA BLVD	ORLANDO	FL	32816	ORANGE	USA	Blood Diseases and Resources Research	000	2	5/21/2024	NON-COMPETING CONTINUATION	$542,119
														Subtotal = $542,119

Issue Date FY: 2023 ( Subtotal = $582,689 )
2023	2023	UNIVERSITY OF CENTRAL FLORIDA BOARD OF TRUSTEES, THE	4000 CENTRAL FLORIDA BLVD	ORLANDO	FL	32816	ORANGE	USA	Blood Diseases and Resources Research	000	1	4/24/2023	NEW	$582,689
														Subtotal = $582,689

Grand Total All Awards = $1,669,068

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting medium chain fatty acid metabolism for the treatment of chronic Graft-versus-Host Disease

Award Number: R01HL166820

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2023

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer